News & Events

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures under the Introductory Note and

are incorporated herein by reference. On June 10, 2026, the Company notified the Nasdaq Stock Market LLC (“ Nasdaq ”) of the anticipated consummation of the Merger and requested that Nasdaq halt trading of the Shares effective as of 8:00 p.m. Eastern Time, on June 10, 2026. On June 11, 2026, the Company (i) notified Nasdaq of the consummation of the Merger and its intent to remove all Shares from listing on The Nasdaq Global Market and (ii) requested that Nasdaq (A) suspend trading of the Sha…

Material Modification to Rights of Security Holders. The disclosures under the Introductory Note, Item 3.01,

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The disclosures under

Entry into a Material Definitive Agreement. On the Closing Date, in connection with the Merger, the Company and U.S. Bank Trust Company, National Association, a national banking association, as trustee under the Indenture, dated as of September 29, 2025 (the “ Indenture ”) governing the Company’s 3.250% Convertible Senior Notes due 2031 (the “ Convertible Notes ”), entered into a supplemental indenture (the “ Supplemental Indenture ”) to the Indenture, effective upon the Effective Time, provi…

Changes in Control of Registrant. The disclosures under the Introductory Note, Item 3.01,

Termination of a Material Definitive Agreement In connection with the consummation of the Offer and the Merger and effective as of, and contingent upon, the Effective Time, the Company terminated the Company 2015 Incentive Plan, the Company 2017 Equity Incentive Plan, and the Company 2021 Equity Inducement Plan. In addition, and also effective immediately prior to, and contingent upon, the Effective Time, the Company terminated the Company 2017 Employee Stock Purchase Plan.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the Merger, (i) each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors and all committees thereof and (ii) John Hess, the sole direc…

Entry into a Material Definitive Agreement. On April 29, 2026, KalVista Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Chiesi Farmaceutici S.p.A., an Italian società per azioni (“ Parent ”), Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”), and KalVista Pharmaceuticals Limited, a private limited company organized under the…

of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition. On January 8, 2026, KalVista Pharmaceuticals, Inc. (the “Company”) issued a press release (the “Press Release”) announcing preliminary global net revenue of approximately $35 million and $49 million for the quarter and the eight month transition period ended December 31, 2025, respectively. The Company’s audited financial statements for the eight month transition period ended December 31, 2025, are not yet available. Accordingly, the preliminary…

of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) Effective October 6, 2025, the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”) appointed Bilal Arif as the Company’s Chief Operating Officer. Prior to joining the Company, Mr. Arif, age 53, served as the Executive Vice President, Chief Technical Operations Officer of Sarepta Therapeutics, Inc., a commercia…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2025, upon the recommendation of the Nominating and Governance Committee of the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”), the Board approved the appointment of Bethany Sensenig (“ Ms. Sensenig ”) to the Board and Audit Committee of the Board (the “ Audit Committee ”) effective immediately,…

Other Events. Purchase Agreement On September 24, 2025, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several initial purchasers named in Schedule I thereto (the “Initial Purchasers”), relating to the Company’s sale of the Notes to the Initial Purchasers in a private placement in reliance on Section 4(a)(2) of the Securities Act and for initial resale by the Initial Purchasers to persons reaso…

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. On September 29, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) completed its previously announced sale of $143.75 million in aggregate principal amount of its 3.250% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the Initial Purchasers’ (as defined below) option to purchase up to an additional $18.75 million in aggregate principal amount of Notes, to the Initial Purchasers in a private placement in relian…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The terms and conditions of the Notes and Indenture described in

of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Other Events. On July 7, 2025, the Company announced that the U.S. Food and Drug Administration (the “FDA”) approved EKTERLY ® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (“HAE”) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE. The FDA approval was based on data from the phase 3 KONFIDENT clinical trial, published in the New England Journal of Medicine .…

Regulation FD Disclosure. On July 7, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) issued a press release titled “KalVista Pharmaceuticals Announces FDA Approval of EKTERLY ® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema.” A copy of the press release is attached hereto as Exhibit 99.1. On July 7, 2025, the Company also updated its corporate presentation. A copy of the updated presentation is attached as Exhibit 99.2 to this report. The information in…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 12, 2025, Jebediah T. Ledell notified KalVista Pharmaceuticals, Inc. (the “Company”) of his decision to resign from his position as Chief Operating Officer of the Company, effective immediately. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf…

Entry into a Material Definitive Agreement. License Supply and Distribution Agreement On April 8, 2025, KalVista Pharmaceuticals, Ltd., a wholly owned subsidiary of KalVista Pharmaceuticals, Inc. (the “Company”) entered into a License, Supply, and Distribution Agreement (the “License Agreement”) with Kaken Pharmaceutical Co., Ltd ( “Kaken”), pursuant to which the Company has licensed commercialization rights in Japan to Kaken for sebetralstat (the “Licensed Product”), an investigational, oral…

of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.